Abstract
Antiplatelet agents are critical in the care of acute coronary syndromes and percutaneous coronary interventions. Clopidogrel was for several years the gold standard; the development of new agents overcoming its main limitations in terms of intensity and onset of action enable a decrease in the rate of recurrent thrombotic events. Ticagrelor is a new P2Y12-ADP receptor antagonist which, unlike clopidogrel and prasugrel, which are thienopyridines, is a reversible agent and has an original mechanism of action. The goal of the present review is to summarize published data on this new-agent which will soon be available for daily clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
